Today, we are proud to officially rebrand from Plus Therapeutics to @cerenome! Our common stock also begins trading today on the @Nasdaq Capital Market under the new ticker symbol $CNSY (previously PSTV). Our transition to Cerenome represents a major milestone in our company's evolution: moving from a radiotherapeutics-focused developer to an integrated CNS oncology company. By combining "cere" (representing the brain/central nervous system) with "nome" (signifying biological insight and data), our new name reflects our dedication to addressing the complex challenges of CNS cancers through a unified approach. While our name and ticker have changed, our commitment to patients, researchers, and clinicians remains stronger than ever. Discover our new look and learn more on our brand new website: cerenome.com @NasdaqExchange

We are pleased to highlight Dr. Marc Hedrick, President and CEO of Plus Therapeutics, Inc. Dr. Hedrick brings extensive experience in executive leadership, having previously served as President, CEO, and Director at Cytori Therapeutics, Inc., and President and CEO of StemSource, Inc. Dr. Hedrick earned his MD from the University of Texas Southwestern Medical School and his MBA from The Anderson School at UCLA in 2005. His unique blend of medical expertise and business acumen makes him a respected leader in the biotechnology sector. Learn more about our team: plustherapeutics.com/our-tea… #PlusTherapeuticsLeadership #ThoughtLeadership #Biotechnology $PSTV

At Plus Therapeutics, we are committed to developing innovative therapies that address some of the most challenging forms of cancer. Our program includes REYOBIQ™ (rhenium Re186 obisbemeda), our lead drug candidate designed for the treatment of recurrent glioblastoma (GBM), leptomeningeal metastases (LM), and pediatric brain cancers (PBCs), such as ependymoma and high-grade glioma. ‌ #PlusTherapeutics #CancerResearch #ClinicalTrials #ReSPECTGBM #ReSPECTLM $PSTV

At Plus Therapeutics, our mission is clear: to solve the toughest challenges in oncology by improving the efficacy, precision and convenience of radiotherapeutics. Under the leadership of our President and CEO, Dr. Marc Hedrick, MD MBA, we're committed to innovation while maintaining a lean and capital-efficient approach. Our strategic investments aim to maximize value for shareholders and benefits for patients. We envision innovative radiotherapeutics that become a global standard of care for cancer. Learn more about our platform here: plustherapeutics.com/our-pla… ‌ #Radiotherapeutics #Oncology #CancerTreatment #CancerResearch #PlusTherapeutics $PSTV